Literature DB >> 15808287

Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States.

Patricia M Meaden1, S Ann Hartlage, Jennifer Cook-Karr.   

Abstract

This study describes the experience of menstruation among normal women, establishing a baseline for comparison with women reporting symptoms of a menstrual disorder. A community-based sample of 900 women kept a daily log of 50 physical, social, and psychological symptoms for a period of time that included two menstrual cycles. Twenty-five items were derived from the DSM-IV criteria for premenstrual dysphoric disorder (PMDD) and 13 from the premenstrual syndrome (PMS) literature. An additional 12 items were positively worded versions of some of the PMDD items. Women were told that the study was about women's health, with no specific reference to menstruation. Time sequence charts revealed that all symptoms peaked on the first day of menses, with severity levels more than 2 S.D. above the mean for each individual symptom. Women were more likely to endorse distress when symptoms were positively worded than when they were negatively worded. This study shows the importance of reducing bias in self-reports of menstrual symptoms, and illustrates the lag between hormonal changes in the luteal phase and the peak of symptom severity at onset of menses. Further research is needed to determine the nature and extent to which women with a presumed disorder vary from this baseline pattern.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808287     DOI: 10.1016/j.psychres.2005.01.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

1.  Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability.

Authors:  Ethan H Beckley; Angela C Scibelli; Deborah A Finn
Journal:  Psychoneuroendocrinology       Date:  2010-12-15       Impact factor: 4.905

2.  Ovarian hormones and borderline personality disorder features: Preliminary evidence for interactive effects of estradiol and progesterone.

Authors:  Tory A Eisenlohr-Moul; C Nathan DeWall; Susan S Girdler; Suzanne C Segerstrom
Journal:  Biol Psychol       Date:  2015-03-30       Impact factor: 3.251

3.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

4.  Sex differences and hormonal influences on response to mechanical pressure pain in humans.

Authors:  William J Kowalczyk; Maria A Sullivan; Suzette M Evans; Adam M Bisaga; Suzanne K Vosburg; Sandra D Comer
Journal:  J Pain       Date:  2009-10-22       Impact factor: 5.820

5.  Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets.

Authors:  S Ann Hartlage; Sally Freels; Nathan Gotman; Kimberly Yonkers
Journal:  Arch Gen Psychiatry       Date:  2012-03

6.  Examination of premenstrual symptoms as a risk factor for depression in postpartum women.

Authors:  Melissa M Buttner; Sarah L Mott; Teri Pearlstein; Scott Stuart; Caron Zlotnick; Michael W O'Hara
Journal:  Arch Womens Ment Health       Date:  2013-01-08       Impact factor: 3.633

7.  Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch.

Authors:  C Neill Epperson; Benjamin Toll; Ran Wu; Zenab Amin; Kathryn A Czarkowski; Peter Jatlow; Carolyn M Mazure; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2010-06-19       Impact factor: 4.492

8.  Premenstrual dysphoric disorder: evidence for a new category for DSM-5.

Authors:  C Neill Epperson; Meir Steiner; S Ann Hartlage; Elias Eriksson; Peter J Schmidt; Ian Jones; Kimberly A Yonkers
Journal:  Am J Psychiatry       Date:  2012-05       Impact factor: 18.112

Review 9.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 10.  Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Authors:  Caroline Fenton; Keri Wellington; Marit D Moen; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.